Tagged with Generics

Hungary Jānis Meikšāns, newly appointed general manager of Teva Hungary, speaks about his first few months in the country. Meikšāns goes on to elaborate on Hungary’s key positioning as a strategic affiliate for Teva with strong R&D and manufacturing operations. Additionally, he highlights Teva’s longstanding commitment to the country not only…

Generics Despite being recently divested from multinational pharma giant Sanofi, Czech firm Zentiva is becoming one of the fastest-growing generics manufacturing companies in Europe, with a swathe of recent international acquisitions strengthening its position.   Zentiva, a Czech Republic-based generics manufacturer, is on a mission to expand its reach after being…

USA The AAM’s Chip Davis examines the roadblocks to greater adoption of biosimilar drugs in the USA, and why they need to be removed to potentially save billions of dollars and increase patient access to lifesaving medications.     In a nutshell: competition brings prices down across the board Biologic drugs…

Switzerland Indian generics powerhouse Dr. Reddy’s has prioritized biosimilars as a key component of the global organization’s ongoing transition into a specialty pharma company.   As one of the first companies in the developing world to branch out into this segment – launching four biosimilar products between 2001 and 2011 –…

UAE LIFEPharma, a subsidiary of UAE-based VPS Healthcare, has signed a Dh 200 million (USD 55 million) deal with Canada’s Apotex to produce 120 million generic tablets and medicines for Motor Neurone Disease annually over the next 10 years.   This partnership is an important milestone, not only for LIFEPharma and…

Generics Christoph Stoller, general manager for Austria and Germany at Teva was recently elected president of Medicines for Europe, the continent-wide association for the generics and biosimilars industries. Stoller plans to focus his efforts on improving access to generics and biosimilars in Europe, as well as tackling the damaging issue of…

Europe Christoph Stoller, the recently appointed president of Medicines for Europe, outlines the mission of his presidency, how the association and its members are working to tackle the issue of drug shortages across the continent, and the crucial importance of establishing a high-level dialogue between industry and governments. Adrian van den…

Opinion The AAM’s Chip Davis tackles the issue of abandonment within US healthcare and proposes three measures to boost competition, thereby lowering drug prices and reducing abandonment rates.   Generic and biosimilar prescription drugs manufactured by member companies of the Association for Accessible Medicines (AAM) play an integral role in the…

Thailand Suchart Chookruvong and Wanna Thanesanont of Thai generics player Polipharm, highlight the growing importance of R&D within their strategy, how the firm has remained focused on quality, and why Polipharm aims to position itself as the partner of choice for all stakeholders in Thailand; a local company with an international…

Sweden Founded in Sweden in 2005, and with operations in 13 European countries, Bluefish Pharmaceuticals has become one of the world’s most progressive generic pharmaceuticals companies. CEO Berit Lindholm explains how Bluefish strives to compete on service rather than price by being a reliable partner to health authorities. She also emphasises…

Sweden Orifarm is the largest supplier of parallel imported medicines in the EU and a fast-growing supplier of generic pharmaceuticals in the Nordic countries. Christian Vallentin, country manager of Orifarm Sweden, explains the intricacies of the parallel import business and generics market in Sweden, how to successfully compete in both areas,…

Pricing Generic drugs foster competition in the pharmaceutical market. Chester “Chip” Davis, Jr.  of the Association for Accessible Medicines (AAM) reveals the data behind generic competition and elaborates on opportunities for further savings.    The American public is clamoring for systemic changes to address skyrocketing drug prices. Specialty drugs—a growing category…